SerpinPC的临床前特征:一种潜在的血友病新疗法
本文报告了活化蛋白C(APC)共价抑制剂SerpinPC的临床前疗效与安全性数据。在血友病A(HA)小鼠尾部切割模型中,SerpinPC以剂量和时间依赖方式减少失血至与野生型(WT)小鼠相当的水平,可治疗活动性出血并经预防性给药防止自发性内出血,未伴炎症反应增加,高剂量在WT动物中耐受良好。SerpinPC目前正在重型血友病患者中评估。
要点
- SerpinPC是活化蛋白C(APC)的共价抑制剂,通过下调抗凝通路恢复止血。
- 在HA小鼠尾部切割模型中,SerpinPC以剂量和时间依赖方式减少失血至WT小鼠水平。
- SerpinPC可治疗HA小鼠活动性出血,预防性给药可防止自发性内出血。
核心结论
- SerpinPC在血友病A小鼠模型中展现出治疗活动性出血和预防自发性内出血的临床前疗效,且未伴炎症反应增加、高剂量耐受良好。
- SerpinPC目前正在重型血友病患者中评估。
研究设计与样本
- 临床前研究:在血友病A(HA)小鼠尾部切割模型中评估SerpinPC的疗效,并在野生型(WT)动物中评估安全性与耐受性。
主要发现
- 在HA小鼠尾部切割模型中,SerpinPC以剂量和时间依赖方式减少失血,降至与WT小鼠相当的水平。
- SerpinPC能够治疗HA小鼠的活动性出血。
- 预防性给予SerpinPC可防止HA小鼠的自发性内出血。
- SerpinPC治疗未伴随炎症反应增加。
- SerpinPC在高剂量下于WT动物中耐受良好。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concept of restoring hemostasis by down-tuning anticoagulant pathways holds the promise of treating all forms of hemophilia. Here, we report preclinical efficacy and safety data for SerpinPC, a covalent inhibitor of activated protein C (APC). APC is a serine protease that degrades the enzyme complex that produces thrombin, and its inhibition allows for more thrombin to be produced during the initiation stage of hemostasis. In a hemophilia A (HA) mouse tail clip model, SerpinPC treatment reduced blood loss in a dose- and time-dependent manner to levels comparable with wild-type (WT) mice. SerpinPC was able to treat active bleeds in HA mice and prevented spontaneous internal bleeding when given prophylactically. SerpinPC treatment was not associated with an increased inflammatory response and was well tolerated at high doses in WT animals. SerpinPC is currently being evaluated in individuals with severe hemophilia.
引用
- Huntington JA, Reckless J, Polderdijk SGI, et al. The preclinical profile of SerpinPC: a potential new treatment for hemophilia. Blood Adv. 2025. PMID: 40086076. doi:10.1182/bloodadvances.2024015201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。